REG - Susquehanna Ire. Ltd Takeda Pharma.Co.Ltd Shire plc - Form 8.3 - Shire plc
RNS Number : 5842LSusquehanna Ireland Ltd27 December 2018FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Full name of discloser:
Susquehanna International Holdings LLC ("SIHL")
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):
The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
N/A
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:
Use a separate form for each offeror/offeree
Shire plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
N/A
(e) Date position held/dealing undertaken:
For an opening position disclosure, state the latest practicable date prior to the disclosure
24th December 2018
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
Takeda Pharmaceutical Company Limited
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant security:
Ordinary Shares ISIN: JE00B2QKY057
ADRs ISIN: US82481R1068
(Each ADR converts to 3 Ordinary Shares)
Interests
Short positions
Number
%
Number
%
(1) Relevant securities owned and/or controlled:
8,615,739
0.939%
91,863
0.01%
(2) Cash-settled derivatives:
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
1,709,600
0.19%
481,400
0.05%
TOTAL:
10,325,339
1.13%
573,263
0.06%
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors' and other employee options)
Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security
Purchase/sale
Number of securities
Price per unit
Ordinary Shares
Purchase
1
44.95
(b) Cash-settled derivative transactions
Class of relevant security
Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities
Price per unit
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of relevant security
Product description e.g. call option
Writing, purchasing, selling, varying etc.
Number of securities to which option relates
Exercise price per unit
Type
e.g. American, European etc.
Expiry date
Option money paid/ received per unit
(ii) Exercise
Class of relevant security
Product description
e.g. call option
Exercising/ exercised against
Number of securities
Exercise price per unit
(d) Other dealings (including subscribing for new securities)
Class of relevant security
Nature of dealing
e.g. subscription, conversion
Details
Price per unit (if applicable)
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached?
YES
Date of disclosure:
27/12/2018
Contact name:
John Kiefel/Olive Fogarty
Telephone number*:
00 353 802 8129/8059
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
SUPPLEMENTAL FORM 8 (OPEN POSITIONS)
DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.
Note 5(i) on Rule 8 of the Takeover Code (the "Code")
1. KEY INFORMATION
Full name of person making disclosure:
Susquehanna International Holdings LLC ("SIH LLC")
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:
Shire Plc
2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)
Class of relevant security
Product description e.g. call option
Written or purchased
Number of securities to which option or derivative relates
Exercise price per unit
Type
e.g. American, European etc.
Expiry date
Option on ord
PUT
Written
448
4000
American
18-Jan-19
Option on ord
PUT
Written
228
4200
American
18-Jan-19
Option on ord
PUT
Written
150
3800
American
15-Mar-19
Option on ord
PUT
Written
141
3800
American
15-Mar-19
Option on ord
PUT
Written
106
3800
American
18-Jan-19
Option on ord
PUT
Written
100
3200
American
20-Dec-19
Option on ord
PUT
Written
25
4400
American
18-Jan-19
Option on ord
PUT
Written
25
4400
American
15-Mar-19
Option on ord
PUT
Written
20
3000
American
21-Jun-19
Option on ord
PUT
Written
15
4400
American
18-Jan-19
Option on ord
PUT
Written
15
3200
American
19-Jun-20
Option on ord
PUT
Written
10
2800
American
18-Jan-19
Option on ord
PUT
Written
10
4600
American
18-Jan-19
Option on ord
PUT
Written
10
3000
American
15-Feb-19
Option on ord
PUT
Written
9
3200
American
15-Feb-19
Option on ord
PUT
Written
5
4000
American
15-Feb-19
Option on ord
PUT
Written
5
3200
American
15-Mar-19
Option on ord
PUT
Written
5
4000
American
20-Sep-19
Option on ADR
PUT
Written
3
150
American
18-Apr-19
Option on ord
PUT
Written
2
4200
American
15-Feb-19
Option on ADR
PUT
Written
1
160
American
18-Jan-19
Option on ADR
CALL
Purchased
1
150
American
18-Apr-19
Option on ord
CALL
Purchased
5
5200
American
20-Sep-19
Option on ord
CALL
Purchased
7
4000
American
18-Jan-19
Option on ADR
CALL
Purchased
8
155
American
18-Apr-19
Option on ord
CALL
Purchased
9
4000
American
15-Mar-19
Option on ord
CALL
Purchased
9
5200
American
18-Apr-19
Option on ord
CALL
Purchased
14
5200
American
15-Feb-19
Option on ADR
CALL
Purchased
19
200
American
18-Jan-19
Option on ord
CALL
Purchased
45
4800
American
18-Jan-19
Option on ord
CALL
Purchased
100
4000
American
20-Dec-19
Option on ord
CALL
Purchased
132
4800
American
15-Mar-19
Option on ord
CALL
Written
70
4400
American
15-Mar-19
Option on ord
PUT
Written
50
4200
American
18-Jan-19
Option on ord
CALL
Written
47
4600
American
18-Jan-19
Option on ord
CALL
Written
18
4600
American
15-Mar-19
Option on ord
CALL
Written
10
5600
American
20-Dec-19
Option on ord
CALL
Written
5
4400
American
18-Jan-19
Option on ord
CALL
Written
5
5600
American
19-Jun-20
Option on ord
CALL
Written
5
4800
American
20-Dec-19
Option on ord
PUT
Purchased
1
4400
American
15-Feb-19
Option on ord
PUT
Purchased
1
4400
American
18-Apr-19
Option on ADR
PUT
Purchased
1
160
American
18-Jan-19
Option on ADR
PUT
Purchased
1
160
American
18-Apr-19
Option on ord
PUT
Purchased
2
3600
American
15-Mar-19
Option on ADR
PUT
Purchased
3
150
American
18-Apr-19
Option on ADR
PUT
Purchased
3
155
American
18-Apr-19
Option on ord
PUT
Purchased
4
3600
American
18-Jan-19
Option on ord
PUT
Purchased
5
2000
American
18-Jan-19
Option on ord
PUT
Purchased
5
2400
American
18-Jan-19
Option on ord
PUT
Purchased
5
3200
American
18-Jan-19
Option on ord
PUT
Purchased
5
3800
American
21-Jun-19
Option on ord
PUT
Purchased
7
3400
American
15-Feb-19
Option on ord
PUT
Purchased
10
4800
American
15-Mar-19
Option on ord
PUT
Purchased
13
4200
American
15-Mar-19
Option on ord
PUT
Purchased
16
4000
American
15-Mar-19
Option on ord
PUT
Purchased
45
4000
American
20-Dec-19
Option on ord
CALL
Written
200
5200
American
18-Jan-19
3. AGREEMENTS TO PURCHASE OR SELL ETC.
Full details should be given so that the nature of the interest or position can be fully understood:
It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.
The currency of all prices and other monetary amounts should be stated.
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDRETTRBTTMBMTBMP
Recent news on Takeda Pharmaceutical Co
See all newsREG - Malin Corp PLC - Malin Announces 2021 Full Year Results
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Confirmation of post-offer intention statements
AnnouncementREG - Morgan Stanley&CoLLC Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI) - Replacement of Takeda
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Statement re Applicable Exchange Rate
AnnouncementREG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - Replacement of Takeda
Announcement